"Accelerating Overseas Market Expansion"

Bukwang Pharmaceutical announced on August 4 that it has signed an exclusive export contract with Pacific Healthcare for the diabetic polyneuropathy treatment 'Dexid Tab (active ingredient: thioctic acid tromethamine salt)' at Pacific Healthcare's headquarters in Bangkok, Thailand.


Jiyoung Lee, CEO of Bukwang Pharmaceutical (left), and Patrick Brulman, CEO of Pacific Healthcare, are posing for a commemorative photo after signing the Dexid export contract to Thailand. Bukwang Pharmaceutical

Jiyoung Lee, CEO of Bukwang Pharmaceutical (left), and Patrick Brulman, CEO of Pacific Healthcare, are posing for a commemorative photo after signing the Dexid export contract to Thailand. Bukwang Pharmaceutical

View original image

Under this agreement, Pacific Healthcare will be responsible for obtaining regulatory approval, marketing, and distribution of Dexid Tab in Thailand, while Bukwang Pharmaceutical will supply the product and provide local regulatory support, officially entering the Thai market.


Dexid Tab is an improved drug formulation of alpha-lipoic acid developed by Bukwang Pharmaceutical and launched in 2014. It is a prescription drug used to treat diabetic polyneuropathy and is recommended as a disease-modifying therapy in diabetes treatment guidelines both in Korea and internationally. It is currently sold in Korea, Cambodia, and the Philippines, with the approval process underway in Vietnam.



Jaeyoung Lee, CEO of Bukwang Pharmaceutical, said, "With this agreement, we plan to accelerate the expansion into overseas markets."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing